Statistik Asas
| LEI | 529900F1BWRE1M0KZN89 |
| CIK | 1299130 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pacific Biosciences of California, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table S-8 (Form Type) Pacific Biosciences of California, Inc. |
|
| August 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2025 Pacific Biosciences of California, Inc. |
|
| August 7, 2025 |
PacBio Announces Second Quarter 2025 Financial Results PacBio Announces Second Quarter 2025 Financial Results MENLO PARK, Calif., August 07, 2025 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025 Q2 2024 Revenue $39.8 million $36.0 million Instrument revenue $14.2 million $14.7 million Consumable revenue $18.9 million $17.0 million Service and other revenue $ |
|
| June 6, 2025 |
Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended Exhibit 10.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN (As Amended May 25, 2022 and June 18, 2024, and As Amended Further Effective June 4, 2025) 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2025 Pacific Biosciences of California, Inc. |
|
| May 29, 2025 |
Conflict Minerals Report of Pacific Biosciences of California, Inc Exhibit 1.01 Conflict Minerals Report of Pacific Biosciences of California, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pacific Biosciences of California, Inc. (“PACB” or the “Company”) for the reporting period January 1, 2024 to December 31, 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Excha |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pacific Biosciences of California, Inc. |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| May 12, 2025 |
Exhibit 10.3 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Effective as of April 22, 2025 Pacific Biosciences of California, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who |
|
| May 12, 2025 |
Letter Relating to Employment Terms by and between Exhibit 10.2 James R. Gibson [***] Dear James, On behalf of Pacific Biosciences of California, Inc. (the “Company”), I am pleased to offer you a position at the Company as Chief Financial Officer (“CFO”). You will be reporting to the Chief Executive Officer. You will receive a salary of $500,000 annually, paid twice monthly according to the Company’s payroll schedule, subject to applicable withhol |
|
| May 12, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 8, 2025 |
PacBio Announces First Quarter 2025 Financial Results PacBio Announces First Quarter 2025 Financial Results MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million $19.0 million Consumable revenue $20.1 million $16.0 million Service and other revenue $6.0 |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2025 Pacific Biosciences of California, Inc. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 9, 2025 |
Exhibit 99.1 PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 9, 2025 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced preliminary, unaud |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2025 Pacific Biosciences of California, Inc. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 24, 2025 Pacific Biosciences of California, Inc. |
|
| March 27, 2025 |
Jim Gibson to join PacBio as Chief Financial Officer Exhibit 99.1 Jim Gibson to join PacBio as Chief Financial Officer MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company’s new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over |
|
| March 17, 2025 |
Outside Director Compensation Policy Exhibit 10.33 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Effective as of April 6, 2024 Pacific Biosciences of California, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who |
|
| March 17, 2025 |
Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated July 22, 2015 Exhibit 10.18 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE (I) IT IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. LEASE BY AND BETWEEN MENLO PARK PORTFOLIO II, LLC, LESSOR AND PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation, LESSEE Menlo Business Park 1315 O |
|
| March 17, 2025 |
Exhibit 10.21 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made as of February 27, 2025 (the “Effective Date”), by and between MENLO PARK PORTFOLIO II, LLC, a Delaware limited liability company (“Lessor”), and PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee are parties to that certain Lease, dated as of July |
|
| March 17, 2025 |
Exhibit 10.20 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made as of December 30, 2019 (the “Effective Date”), by and between MENLO PARK PORTFOLIO II, LLC, a Delaware limited liability company (“Lessor”) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee entered into that certain Lease, dated as of July 2 |
|
| March 17, 2025 |
Exhibit 10.17 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Mark Van Oene (“Executive”) and Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), effective as of December 12, 2024 (the “Effe |
|
| March 17, 2025 |
Exhibit 10.15 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Christian O. Henry (“Executive”) and Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), effective as of December 11, 2024 (the |
|
| March 17, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary name Jurisdiction Type Pacific Biosciences International LLC Delaware Domestic Pacific Biosciences Canada Limited Canada (Ontario) Foreign Pacific Biosciences Germany GmbH Germany (Munich) Foreign Pacific Biosciences Japan GK Japan (Tokyo) Foreign Pacific Biosciences (Shanghai) Co., Ltd. China (Shanghai) Foreign PacBio Singapore Pte. Limited Singapore F |
|
| March 17, 2025 |
Description of Registrant’s securities registered under Section 12 of the Exchange Act Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation (as amended, the “amended and restated certificate of incorporation”) and amended |
|
| March 17, 2025 |
Exhibit 10.19 CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE (I) IT IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is made as of December 23, 2016 (the “Effective Date”), by and between MENLO PARK PORT |
|
| March 17, 2025 |
Calculation of Filing Fee Table Form S-8 (Form Type) Pacific Biosciences of California, Inc. |
|
| March 17, 2025 |
Form of Change in Control and Severance Agreement for executive officers Exhibit 10.13 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between [] (“Executive”) and Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), effective as of [], 202[] (the “Effective Date”). RECITALS 1.It is expected that the Company from |
|
| March 17, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348 |
|
| March 17, 2025 |
As filed with the Securities and Exchange Commission on March 17, 2025 As filed with the Securities and Exchange Commission on March 17, 2025 Registration No. |
|
| March 17, 2025 |
Exhibit 19.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. INSIDER TRADING POLICY (As amended and restated on October 30, 2024) A.POLICY OVERVIEW Pacific Biosciences of California, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in sec |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2025 Pacific Biosciences of California, Inc. |
|
| February 13, 2025 |
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results Exhibit 99.1 PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) - PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results •Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period. •Instrument revenue of $15.3 mi |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2025 Pacific Biosciences of California, Inc. |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2025 Pacific Biosciences of California, Inc. |
|
| January 30, 2025 |
Exhibit 99.1 PacBio Announces Appointment of Chris Smith to Board of Directors PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of C |
|
| January 14, 2025 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2025 Pacific Biosciences of California, Inc. |
|
| January 14, 2025 |
Exhibit 99.1 PacBio Announces Preliminary Fourth Quarter and Full Year Revenue Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate se |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025 Registration No. |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. |
|
| December 13, 2024 |
Separation Agreement and Release, dated December 6, 2024 and effective December 13, 2024 Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Jeff Eidel (“Employee”) and Pacific Biosciences of California, Inc. (the “Company”) (jointly referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee was employed at-will by the Company; WHEREAS, Employee signed an At-Will Employment, Confidentia |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2024 Pacific Biosciences of California, Inc. |
|
| December 10, 2024 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2024 Pacific Biosciences of California, Inc. |
|
| November 26, 2024 |
PACB / Pacific Biosciences of California, Inc. / SOFTBANK GROUP CORP - SC 13G Passive Investment SC 13G 1 ef20039294sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) November 21, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2024 Pacific Biosciences of California, Inc. |
|
| November 22, 2024 |
exhibit41final PACIFIC BIOSCIENCES OF CALIFORNIA, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of November 21, 2024 1.50% Convertible Senior Notes due 2029 Exhibit 4.1 i 4819-2579-9899 v.5 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions ................................................................................................... |
|
| November 22, 2024 |
Letter Agreement, dated November 21, 2024, between the Company and SB Northstar LP Exhibit 10.1 SIDE LETTER AGREEMENT The Side Letter Agreement (as amended, restated, modified or supplemented from time to time, the “Agreement”), dated as of November 21, 2024, is made by and between SB Northstar LP (the “Holder”) and Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), in connection with the issuance by the Company of its 1.50% Convertible Senior Notes |
|
| November 14, 2024 |
SC 13G 1 ss4037903sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69404D108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 14, 2024 |
SC 13G/A 1 tm2427620d17sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing o |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 11, 2024 Pacific Biosciences of California, Inc. |
|
| November 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 8, 2024 |
PACB / Pacific Biosciences of California, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 PACBSC13GNov2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 69404D108 (CUSIP Number) NOVEMBER 4, 2024 (Date of event which requires filing of this statement) Check the approp |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2024 Pacific Biosciences of California, Inc. |
|
| November 7, 2024 |
Exhibit 99.1 PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) - PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of |
|
| November 7, 2024 |
Letter Agreement, dated November 7, 2024, between the Company and SB Northstar LP Exhibit 10.1 EXECUTION VERSION PACIFIC BIOSCIENCES OF CALIFORNIA, INC. November 7, 2024 Ladies and Gentlemen: Reference is hereby made to (i) the $200,000,000 aggregate principal amount of the 1.50% Convertible Senior Notes due 2029 (the “Notes”) to be issued by Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), pursuant to the Indenture, to be dated on or about Novem |
|
| November 7, 2024 |
PacBio Announces Third Quarter 2024 Financial Results Exhibit 99.1 PacBio Announces Third Quarter 2024 Financial Results MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: • Revenue of $40.0 million compared with $55.7 million in the prior-year period. • Instrument revenue of $16.8 million compared with $34.7 million in the prior |
|
| November 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2024 Pacific Biosciences of California, Inc. |
|
| August 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 Pacific Biosciences of California, Inc. |
|
| August 7, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. |
|
| August 7, 2024 |
PacBio Announces Second Quarter 2024 Financial Results PacBio Announces Second Quarter 2024 Financial Results MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) - - PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: •Revenue of $36.0 million compared with $47.6 million in the prior-year period. •Instrument revenue of $14.7 million compared with $29.9 million in the prior-year period. In |
|
| June 20, 2024 |
Form of Global Stock Option Agreement under the 2020 Equity Incentive Plan, as amended Exhibit 10.2 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Global Stock Option Agreement which includes the Notice of Stock Option Grant ( |
|
| June 20, 2024 |
2020 Equity Incentive Plan, as amended Exhibit 10.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN (As Amended May 25, 2022 and As Amended Further Effective June 18, 2024) 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and •to promote the s |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 20, 2024 As filed with the Securities and Exchange Commission on June 20, 2024 Registration No. |
|
| June 20, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Pacific Biosciences of California, Inc. |
|
| June 20, 2024 |
Form of Global Restricted Stock Unit Agreement under 2020 Equity Incentive Plan, as amended Exhibit 10.3 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Global Restricted Stock Unit Agreement which includes the Not |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2024 Pacific Biosciences of California, Inc. |
|
| June 20, 2024 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Pacific Biosciences of California, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is Pacific Biosciences of California, Inc. The Corporation’s orig |
|
| June 20, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Pacific Biosciences of California, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is Pacific Biosciences of California, Inc. The Corporation’s orig |
|
| May 30, 2024 |
2023 Conflict Minerals Report of Pacific Biosciences of California, Inc Exhibit 1.01 Conflict Minerals Report of Pacific Biosciences of California, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pacific Biosciences of California, Inc. (“PACB” or the “Company”) for the reporting period January 1, 2023 to December 31, 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Excha |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pacific Biosciences of California, Inc. |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Pacific Biosciences of California, Inc. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2024 Pacific Biosciences of California, Inc. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
PacBio Announces First Quarter 2024 Financial Results PacBio Announces First Quarter 2024 Financial Results MENLO PARK, Calif. – May 9, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024. First quarter results: •Revenue of $38.8 million compared with $38.9 million in the prior-year period. •Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. Instrument |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2024 Pacific Biosciences of California, Inc. |
|
| April 16, 2024 |
Exhibit 99.1 PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. – April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 20 |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission on April 11, 2024 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No. |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission on April 11, 2024 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No. |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission on April 11, 2024 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No. |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 29, 2024 |
Calculation of Filing Fee Table Form S-8 (Form Type) Pacific Biosciences of California, Inc. |
|
| February 28, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348 |
|
| February 28, 2024 |
4853-9957-6739.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Performance-Based Restricted Stock Unit Agreem |
|
| February 28, 2024 |
Exhibit 97.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. COMPENSATION RECOVERY POLICY As most recently amended on October 24, 2023 Pacific Biosciences of California, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Poli |
|
| February 28, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary name Jurisdiction Type Pacific Biosciences International LLC Delaware Domestic Pacific Biosciences Canada Limited Canada (Ontario) Foreign Pacific Biosciences Germany GmbH Germany (Munich) Foreign Pacific Biosciences Japan GK Japan (Tokyo) Foreign Pacific Biosciences (Shanghai) Co., Ltd. China (Shanghai) Foreign PacBio Singapore Pte. Limited Singapore F |
|
| February 15, 2024 |
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results MENLO PARK, Calif. |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 15, 2024 Pacific Biosciences of California, Inc. |
|
| February 13, 2024 |
SC 13G/A 1 tm245429d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t |
|
| February 12, 2024 |
SC 13G/A 1 ef20021452sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t |
|
| February 9, 2024 |
SC 13G/A 1 tm245549d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Pacific Biosciences of California Inc (Name of Issuer) Common (Title of Class of Securities) 69404 |
|
| February 5, 2024 |
SC 13G/A 1 pacbio130247sc13ga2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2023 (Date of Event which Requires |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 10, 2024 |
SC 13G/A 1 tv0020-pacificbiosciencesofc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Pacific Biosciences of California Inc Title of Class of Securities: Common Stock CUSIP Number: 69404D108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appr |
|
| January 8, 2024 |
PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively Ships a record number of PacBio sequencers in 2023, including 173 RevioTM systems, and announces record fourth quarter preliminary consumable revenue of $18. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2024 Pacific Biosciences of California, Inc. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2023 Pacific Biosciences of California, Inc. |
|
| November 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 30, 2023 |
PacBio Announces Third Quarter 2023 Financial Results PacBio Announces Third Quarter 2023 Financial Results MENLO PARK, Calif. – Oct. 30, 2023 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results •Revenue of $55.7 million, a 72% increase compared with $32.3 million in the prior-year period. •Instrument revenue of $34.7 million compared with $11.4 million in the prior-ye |
|
| October 30, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2023 Pacific Biosciences of California, Inc. |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| October 16, 2023 |
PacBio Announces Appointment of David Meline to Board of Directors Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif. |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 16, 2023 Pacific Biosciences of California, Inc. |
|
| October 3, 2023 |
As filed with the Securities and Exchange Commission on October 3, 2023 As filed with the Securities and Exchange Commission on October 3, 2023 Registration No. |
|
| October 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Pacific Biosciences of California, Inc. |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| August 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 4, 2023 |
pacb-ex41x2021indenture Exhibit 4.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of February 16, 2021 1.50% Convertible Senior Notes due 2028 i TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions ................................................................................................................ 1 Section 1 |
|
| August 2, 2023 |
PacBio Begins Commercialization of the Onso Short-Read Sequencing System The Onso platform delivers extraordinary accuracy which creates new possibilities for research and translational sequencing applications MENLO PARK, Calif. |
|
| August 2, 2023 |
PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer PacBio will combine Apton’s proprietary sequencing technology with its highly accurate Sequencing by Binding chemistry to develop a high-throughput sequencer designed to deliver billions of reads per flow cell MENLO PARK, Calif. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2023 Pacific Biosciences of California, Inc. |
|
| August 2, 2023 |
PacBio Announces Second Quarter 2023 Financial Results PacBio Announces Second Quarter 2023 Financial Results Menlo Park, Calif. – August 2, 2023 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023. Second quarter results •Revenue of $47.6 million, a 34% increase compared with $35.5 million in the prior-year period. •Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2023 Pacific Biosciences of California, Inc. |
|
| June 30, 2023 |
Exhibit 4.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 30, 2023 1.375% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 12 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Design |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2023 Pacific Biosciences of California, Inc. |
|
| June 26, 2023 |
Exhibit 99.1 PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030 MENLO PARK, CA. – June 26, 2023 – Pacific Biosciences of California, Inc. ("PacBio") (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio’s outstanding 1.50% Convertible Senior Note |
|
| June 26, 2023 |
Letter Agreement, dated June 23, 2023, between the Company and Chimera Investment LLC Exhibit 10.1 Execution Version PACIFIC BIOSCIENCES OF CALIFORNIA, INC. June 23, 2023 Ladies and Gentlemen: Reference is hereby made to the $441,000,000 aggregate principal amount of the 1.375% Convertible Senior Notes due 2030 (the “Notes”) to be issued by Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), pursuant to the Indenture, dated on or about June 23, 2023 (th |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2023 Pacific Biosciences of California, Inc. |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pacific Biosciences of California, Inc. |
|
| May 24, 2023 |
2022 Conflict Minerals Report of Pacific Biosciences of California, Inc EX-1.01 2 exhibit101-2022.htm EX-1.01 Exhibit 1.01 Conflict Minerals Report of Pacific Biosciences of California, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pacific Biosciences of California, Inc. (“PACB” or the “Company”) for the reporting period January 1, 2022 to December 31, 2022 in accordance with Rule 13p-1 (“R |
|
| May 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2023 Pacific Biosciences of California, Inc. |
|
| May 2, 2023 |
PacBio Announces Record Revenue in First Quarter 2023 PacBio Announces Record Revenue in First Quarter 2023 Menlo Park, Calif. – May 2, 2023 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023. First quarter results •Revenue of $38.9 million, a 17% increase compared with $33.2 million in the prior year period. •Shipped 38 sequencing systems in the first quarter, including 32 Revio systems and 6 Sequel IIe sy |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 13, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Pacific Biosciences of California, Inc. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific Bioscienc |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES Subsidiary name Jurisdiction Type Pacific Biosciences International LLC Delaware Domestic Pacific Biosciences Canada Limited Canada (Ontario) Foreign Pacific Biosciences Germany GmbH Germany (Munich) Foreign Pacific Biosciences Japan GK Japan (Tokyo) Foreign Pacific Biosciences (Shanghai) Co., Ltd. China (Shanghai) Foreign PacBio Singapore Pte. Limited Singapo |
|
| February 28, 2023 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Performance-Based Restricted Stock Unit Agreement which include |
|
| February 16, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2023 Pacific Biosciences of California, Inc. |
|
| February 16, 2023 |
PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results Menlo Park, Calif. |
|
| February 13, 2023 |
SC 13G/A 1 tm236452d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of t |
|
| February 13, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69404D108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 10, 2023 |
SC 13G/A 1 brhc10047833sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Pacific Biosciences of California Inc (Name of Issuer) Common (Title of Class of Securities) 69404D108 (CUSIP Number) 12/31/2022 (Date of E |
|
| February 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Pacific Biosciences of California Inc. Title of Class of Securities: Common Stock CUSIP Number: 69404D108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this S |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2023 Pacific Biosciences of California, Inc. |
|
| January 27, 2023 |
Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock Exhibit 99.1 Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock MENLO PARK, CA, January 24, 2023, Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“PacBio”) today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has |
|
| January 27, 2023 |
Exhibit 1.1 Execution Version PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 17,500,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement January 24, 2023 Goldman Sachs & Co. LLC Morgan Stanley & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule A hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Morgan |
|
| January 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Pacific Biosciences of California, Inc. |
|
| January 25, 2023 |
17,500,000 shares Pacific Biosciences of California, Inc. COMMON STOCK TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-249999 PROSPECTUS SUPPLEMENT (To Prospectus dated November 10, 2020) 17,500,000 shares Pacific Biosciences of California, Inc. COMMON STOCK We are offering 17,500,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “PACB.” On January 24, 2023, the last reported sale |
|
| January 24, 2023 |
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock MENLO PARK, CA, January 24, 2023, Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“PacBio”) today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to |
|
| January 24, 2023 |
pacb.com | 650.521.8000 | 1305 O’Brien Dr. Menlo Park, CA 94025 Exhibit 99.3 Jeff Eidel [***] Dear Jeff, On behalf of Pacific Biosciences of California, Inc. (the “Company”), I am pleased to offer you a position at the Company as Chief Commercial Officer. You will report directly to me and be responsible for all commercial activity at PacBio. You will receive a salary of $438,000 annually, paid twice monthly according to the Company’s payroll schedule. You wil |
|
| January 24, 2023 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 99.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Susan Kim (“Executive”) and Pacific Biosciences of California, Inc., a Delaware corporation (the “Company”), effective as of February 3, 2021 (the “Effective Date”). RECITALS 1. It is expected that th |
|
| January 24, 2023 |
SUBJECT TO COMPLETION, DATED JANUARY 24, 2023 TABLE OF CONTENTS This preliminary prospectus supplement and accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 24, 2023 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2023 Pacific Biosciences of California, Inc. |
|
| January 24, 2023 |
Potential Payments upon Involuntary Termination or Change in Control Exhibit 99.2 RISK FACTORS You should consider carefully the risks and uncertainties described below, together with all of the other information in our public filings with the SEC, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that |
|
| January 9, 2023 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2023 Pacific Biosciences of California, Inc. |
|
| January 9, 2023 |
EX-99.1 2 pacb-20230109xex991.htm EX-99.1 Exhibit 99.1 PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022 PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif., January 9, 2023 (PRNewswire) – PacBio (NASDAQ: PACB), a leading developer o |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific |
|
| November 7, 2022 |
Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc. ? ? ? THIRD AMENDED AND RESTATED BYLAWS OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC. |
|
| November 7, 2022 |
PacBio Announces Third Quarter 2022 Financial Results Exhibit 99.1 PacBio Announces Third Quarter 2022 Financial Results Menlo Park, Calif. ? November 7, 2022 ? PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022. Third quarter results ? Revenue of $32.3 million, a 7% decrease compared with $34.9 million in the prior year period. ? Instrument revenue of $11.4 million, compared with $15.9 million in the pri |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 Pacific Biosciences of California, Inc. |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2022 Pacific Biosciences of California, Inc. |
|
| October 26, 2022 |
Exhibit 99.1 PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15. Withdraws Guidance with New Product Announcement MENLO PARK, Calif., October 25, 2022 – PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, November 7, 2022, at 5:00 pm Eastern Time. PacBi |
|
| August 8, 2022 |
? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific Biosc |
|
| August 3, 2022 |
PacBio Announces Second Quarter 2022 Financial Results Exhibit 99.1 PacBio Announces Second Quarter 2022 Financial Results Menlo Park, Calif. ? August 3, 2022 ? PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022. Second quarter results ? ? Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period. ? Delivered 36 Sequel II/IIe systems, compared with 38 Sequel II/IIe systems in |
|
| August 3, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2022 Pacific Biosciences of California, Inc. |
|
| June 30, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2022 Pacific Biosciences of California, Inc. |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) March 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| May 26, 2022 |
Exhibit 10.3 /$CurrentDate$/ PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Global Restricted Stock Unit Agreement which |
|
| May 26, 2022 |
Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended Exhibit 10.1 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN (As Amended Effective May 25, 2022) 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. |
|
| May 26, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Pacific Biosciences of California, Inc. |
|
| May 26, 2022 |
As filed with the Securities and Exchange Commission on May 26, 2022 As filed with the Securities and Exchange Commission on May 26, 2022 Registration No. |
|
| May 26, 2022 |
As filed with the Securities and Exchange Commission on May 26, 2022 POS AM 1 tm2216799d1posam.htm POS AM As filed with the Securities and Exchange Commission on May 26, 2022 Registration No. 333-187363 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (Exact name of Registrant as specified in its charter) |
|
| May 26, 2022 |
Exhibit 10.2 ###CurrentDate### PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Global Stock Option Agreement which includes the Notice of St |
|
| May 26, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2022 Pacific Biosciences of California, Inc. |
|
| May 25, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pacific Biosciences of California, Inc. |
|
| May 25, 2022 |
Exhibit 1.01 ? Conflict Minerals Report of Pacific Biosciences of California, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 ? This is the Conflict Minerals Report (?CMR?) of Pacific Biosciences of California, Inc. (?PACB? or the ?Company?) for the reporting period January 1, 2021 to December 31, 2021 in accordance with Rule 13p-1 (?Rule 13p-1?) under the Securities E |
|
| May 24, 2022 |
DEFA14A 1 tm2216686d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2022 Pacific Biosciences of California, Inc. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific Bios |
|
| May 6, 2022 |
DocuSign Envelope ID: DE71458D-460C-4C40-8FB7-0CFDB7452F9B ? PACIFIC BIOSCIENCES OF CALIFORNIA, INC. |
|
| May 4, 2022 |
PacBio Announces First Quarter 2022 Financial Results PacBio Announces First Quarter 2022 Financial Results Menlo Park, Calif. ? May 4, 2022 ? PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results ? ? Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period. ? Delivered a record 50 Sequel II/IIe systems during the quarter compared to 41 Sequel II/IIe sy |
|
| May 4, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2022 Pacific Biosciences of California, Inc. |
|
| April 14, 2022 |
DEF 14A 1 tm2212363-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 14, 2022 |
DEFA14A 1 tm2212363d2def14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Comm |
|
| February 28, 2022 |
EX-FILING FEES 5 d292548dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 Pacific Biosciences of California, Inc. Security Type Security Class Title Fee Calculation Rule (3) Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (4) Equity Common stock, $0.001 par value per share Othe |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific Bioscienc |
|
| February 28, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES ? ? Subsidiary name Jurisdiction Type ? Pacific Biosciences International LLC Delaware Domestic ? Pacific Biosciences Canada Limited Canada (New Brunswick) Foreign ? Pacific Biosciences Germany GmbH Germany (Munich) Foreign ? Pacific Biosciences Japan GK Japan (Tokyo) Foreign ? Pacific Biosciences (Shanghai) Co., Ltd. China (Shanghai) Foreign ? PacBio Singapore PT |
|
| February 28, 2022 |
Power of Attorney (contained on signature page hereto) Be As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 15, 2022 |
PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results Menlo Park, Calif. |
|
| February 15, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 15, 2022 Pacific Biosciences of California, Inc. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Pacific Biosciences of California Inc. Title of Class of Securities: Common Stock CUSIP Number: 69404D108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this S |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1 )* Pacific Biosciences of California Inc (Name of Issuer) Common (Title of Class of Securities) 69404D108 (CUSIP Number) 1/31/2022 (Date of E |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Pacific Biosciences of California, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| January 11, 2022 |
Exhibit 99.1 ? PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations MENLO PARK, Calif. ? January 11, 2022 ? PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, |
|
| January 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 11, 2022 Pacific Biosciences of California, Inc. |
|
| November 22, 2021 |
As filed with the Securities and Exchange Commission on November 22, 2021 As filed with the Securities and Exchange Commission on November 22, 2021 ? Registration No. |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 19, 2021 Pacific Biosciences of California, Inc. |
|
| November 19, 2021 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2020 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted December 2, 2020,First Amended April 18, 2021 and Subsequently Amended November 19, 2021 ) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employme |
|
| November 5, 2021 |
Exhibit 10.4 OMNIOME EQUITY INCENTIVE PLAN OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1. Purposes of the Plan. In connection with the Merger, the shares of common stock of Omniome are being assumed and converted into Shares that will be available for grant and issuance under the Plan, consistent with Nasdaq Listing Rule 5635(c). This Omniome Equity Incentive Plan of Pacific Biosciences of Californ |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific |
|
| November 2, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2021 Pacific Biosciences of California, Inc. |
|
| November 2, 2021 |
PacBio Announces Third Quarter 2021 Financial Results PacBio Announces Third Quarter 2021 Financial Results Menlo Park, Calif. ? November 2, 2021 ? PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2021. Record revenue reflects 6th straight quarter of sequential growth ? Revenue of $34.9 million, an 83% increase compared with $19.1 million in the prior year period. ? Placed 44 Sequel II/IIe systems during the |
|
| October 13, 2021 |
Shares of Common Stock Pacific Biosciences of California, Inc. Filed Pursuant to Rule 424(b)(7) Registration No. 333-259670 PROSPECTUS SUPPLEMENT NO. 1 Dated October 13, 2021 (To prospectus dated September 20, 2021) Shares of Common Stock Pacific Biosciences of California, Inc. This Prospectus Supplement No. 1 amends and supplements the prospectus dated September 20, 2021 included in a registration statement that we filed with the SEC using the ?shelf? regist |
|
| September 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2021 Pacific Biosciences of California, Inc. |
|
| September 20, 2021 |
Exhibit 99.2 OMNIOME, INC. (A Delaware Corporation) Financial Statements December 31, 2020 and 2019 (With Independent Auditors? Report Thereon) ? Independent Auditors? Report The Board of Directors Omniome, Inc. Report on the Financial Statements We have audited the accompanying financial statements of Omniome, Inc., which comprise the balance sheets as of December 31, 2020 and 2019, and the relat |
|
| September 20, 2021 |
As filed with the Securities and Exchange Commission on September 20, 2021 As filed with the Securities and Exchange Commission on September 20, 2021 Registration No. |
|
| September 20, 2021 |
Exhibit 99.1 Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence ? Omniome?s high accuracy short-read sequencing platform expected to significantly expand PacBio?s market opportunity ? Acquisition expected to accelerate the adoption of SMRT Sequencing, PacBio?s leading long-read sequencing platform ? PacBio also closes $300 million PIPE financing in support of tran |
|
| September 20, 2021 |
OMNIOME, INC. (A Delaware Corporation) Condensed Financial Statements June 30, 2021 (Unaudited) Exhibit 99.3 OMNIOME, INC. (A Delaware Corporation) Condensed Financial Statements June 30, 2021 (Unaudited) ? OMNIOME, INC. (A Delaware Corporation) Table of Contents ? ? Page Condensed Financial Statements (Unaudited) Balance Sheets 2 Statements of Operations and Comprehensive Loss 3 Statements of Stockholders? Equity 4 Statements of Cash Flows 5 Notes to Condensed Financial Statements (Unaudite |
|
| September 20, 2021 |
Exhibit 4.1 OMNIOME EQUITY INCENTIVE PLAN OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1. Purposes of the Plan. In connection with the Merger, the shares of common stock of Omniome are being assumed and converted into Shares that will be available for grant and issuance under the Plan, consistent with Nasdaq Listing Rule 5635(c). This Omniome Equity Incentive Plan of Pacific Biosciences of Californi |
|
| September 20, 2021 |
As filed with the Securities and Exchange Commission on September 20, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 20, 2021 Registration No. |
|
| September 20, 2021 |
As filed with the Securities and Exchange Commission on September 20, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 20, 2021 Registration No. |
|
| September 20, 2021 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION ? On September, 20, 2021 (?Closing Date?), Pacific Biosciences of California, Inc. (?Pacific Biosciences? or the ?Company?) completed the acquisition of Omniome, Inc. (the ?Target? or ?Omniome?), a San Diego-based company developing a highly differentiated, proprietary short-read seque |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 10, 2021 Pacific Biosciences of California, Inc. |
|
| August 6, 2021 |
Exhibit 10.2 ? March 23, 2021 ? ? Michele Farmer ? ? Dear Michele, ? On behalf of Pacific Biosciences of California, Inc. (the ?Company?), I am pleased to offer you a position at the Company as Chief Accounting Officer. You will be reporting to Susan Kim. ? You will receive a salary of $295,000 annually, paid twice monthly according to the Company?s payroll schedule. ? We have also agreed to provi |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific Biosc |
|
| August 6, 2021 |
Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ? AMENDMENT NO. 1 TO DEVELOPMENT AND COMMERCIALIZATION AGREEMENT ? This Amendment No. 1 to the Development and Commercialization Agreement (?Amendment?) amends the Developmen |
|
| August 3, 2021 |
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results Exhibit 99.1 Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results Menlo Park, Calif. ? August 3, 2021 ? Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021. Record second quarter revenue reflects continued quarter-over-quarter growth Revenue for the second quarter of 2021 was $30.6 million, |
|
| August 3, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2021 Pacific Biosciences of California, Inc. |
|
| July 20, 2021 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of July 19, 2021 by and between Pacific Biosciences of California, Inc., a Delaware corporation (the ?Company?), and each of the Investors named in Exhibit A to that certain Securities Purchase Agreement by and between the Company and each of the Investors, dated as of July |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19, 2021 Pacific Biosciences of California, Inc. |
|
| July 20, 2021 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of July 19, 2021 by and between Pacific Biosciences of California, Inc., a Delaware corporation (the ?Company?), and each of the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors |
|
| July 20, 2021 |
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome Exhibit 99.1 Pacific Biosciences Signs Definitive Agreement to Acquire Omniome ? Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets ? Brings together Omniome?s high accuracy short-read sequencing platform, with PacBio?s market leading, high accuracy long-read solutions ? Transaction supported by concurrent $300 milli |
|
| July 20, 2021 |
Exhibit 10.1 Execution Version AGREEMENT AND PLAN OF MERGER AND PLAN OF REORGANIZATION among PACIFIC BIOSCIENCES OF CALIFORNIA, INC. APOLLO ACQUISITION CORP. APOLLO ACQUISITION SUB, LLC. OMNIOME, INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Securityholder Representative July 19, 2021 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 The Mergers 2 1.2 General Effects of the Mergers. 4 1.3 E |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2021 Pacific Biosciences of California, Inc. |
|
| June 1, 2021 |
? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pacific Biosciences of California, Inc. |
|
| June 1, 2021 |
Exhibit 1.01 ? Conflict Minerals Report of Pacific Biosciences of California, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 ? This is the Conflict Minerals Report (?CMR?) of Pacific Biosciences of California, Inc. (?PACB? or the ?Company?) for the reporting period January 1, 2020 to December 31, 2020 in accordance with Rule 13p-1 (?Rule 13p-1?) under the Securities E |
|
| May 19, 2021 |
May 19, 2021 Via EDGAR and E-mail Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2021 Pacific Biosciences of California, Inc. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pacific Bios |
|
| April 30, 2021 |
DEF 14A 1 pacb-20210616xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by R |
|
| April 30, 2021 |
DEFA14A 1 pacb-20210616xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☑Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the C |
|
| April 29, 2021 |
Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results Exhibit 99.1 Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results Menlo Park, Calif. ? April 29, 2021 ? Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021. Record first quarter revenue reflects a strong start to 2021 Revenue for the first quarter of 2021 was $29.0 million, representing an 8 |
|
| April 29, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2021 Pacific Biosciences of California, Inc. |
|
| April 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2021 Pacific Biosciences of California, Inc. |
|
| April 27, 2021 |
Pacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors Exhibit 99.1 Pacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) ? Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr. Hannah Valantine has been nominated for election to the Company?s Board of Directors as a Class II director |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2021 Pacific Biosciences of California, Inc. |
